DNA sequence analysis and genotyping of biological samples using innovative instrumentation, such as next-generation sequencing (NGS) platforms, is often limited by the small amount of sample available. The REPLI-g Single Cell Kit is specially designed to uniformly amplify genomic DNA from single cells (1 to <1000 bacterial or tumor cells) or purified genomic DNA with complete genome coverage. Additional protocols are also available for use with fresh or dried blood or fresh or frozen tissue. Dedicated buffers and reagents undergo a unique, controlled decontamination procedure to avoid amplification of contaminating DNA, ensuring highly reliable results every time. Accurate amplification of genomes with negligible sequence bias and no genomic drop-outs is achieved with innovative Multiple Displacement Amplification (MDA) technology. In contrast to PCR-based WGA technologies, high fidelity rates are increased up to 1000-fold, avoiding costly false positive or negative results.
Presentation carried out by Sergi Beltran Agulló, from the CNAG, at the course: Identification and analysis of sequence variants in sequencing projects: fundamentals and tools .
DNA sequence analysis and genotyping of biological samples using innovative instrumentation, such as next-generation sequencing (NGS) platforms, is often limited by the small amount of sample available. The REPLI-g Single Cell Kit is specially designed to uniformly amplify genomic DNA from single cells (1 to <1000 bacterial or tumor cells) or purified genomic DNA with complete genome coverage. Additional protocols are also available for use with fresh or dried blood or fresh or frozen tissue. Dedicated buffers and reagents undergo a unique, controlled decontamination procedure to avoid amplification of contaminating DNA, ensuring highly reliable results every time. Accurate amplification of genomes with negligible sequence bias and no genomic drop-outs is achieved with innovative Multiple Displacement Amplification (MDA) technology. In contrast to PCR-based WGA technologies, high fidelity rates are increased up to 1000-fold, avoiding costly false positive or negative results.
Presentation carried out by Sergi Beltran Agulló, from the CNAG, at the course: Identification and analysis of sequence variants in sequencing projects: fundamentals and tools .
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...QIAGEN
Pyrosequencing is a highly flexible technology based on sequencing-by-synthesis for the rapid and quantitative analysis of any type of sequence variation. The real-time output delivers high-resolution sequence information, making pyrosequencing highly suitable for applications ranging from biallelic or multiallelic SNP analysis, DNA methylation quantification to complex mutation analysis of multiple sequence variations in a single run.
In this slideeck, we introduce the new PyroMark Q48 Autoprep system which enables fully automated template preparation integrated in the pyrosequencing workflow. In addition, a new Multiple Primer Dispensation (MPD) strategy is presented which allows fully automated dispensation of sequencing primer, offering a seamless workflow from samples to quantitative genotyping results.
This slidedeck focuses on the following topics
• Pyrosequencing technology and workflow in genotyping analysis
• Introduction into the new PyroMark Q48 Autoprep
• MPD strategy for a seamless automated pyrosequencing workflow
Join us and learn how you can apply the new pyrosequencing system and protocol to your variant analysis or genotyping research
Molecular QC: Using Reference Standards in NGS PipelinesCandy Smellie
Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run.
By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications.
Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.
Molecular QC: Interpreting your Bioinformatics PipelineCandy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all!
FFPE artifacts increase with storage time
Artifacts go against the statistical power of your variant calling analysis
Molecular reference standards help filter out bad mappings and spurious variants
Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline
Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis
NIST and its collaborators shared datasets created with most NGS technologies
Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio
~35K variants are predicted having high or moderate impact within the Trio
GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother
Routinely monitor the performance of your workflows and assays with independent external controls
This slidedeck details two comprehensive informatics solutions — the Biomedical Genomics Workbench and Ingenuity Knowledge Base Variant Analysis platforms. We show the intuitive user interface of CLC Cancer Research Workbench and demonstrate how the rich biological content from Ingenuity Knowledge Base helps you rapidly identify critical variants in your samples.
Digital RNAseq for Gene Expression Profiling: Digital RNAseq Webinar Part 2QIAGEN
Traditional RNA sequencing (RNA-Seq) is a powerful tool for expression profiling, but is hindered by PCR amplification bias and inaccuracy at low expressing genes. QIAseq RNA is a flexible and precise tool developed for mitigating these complications, allowing digital gene expression analysis. In this webinar we will cover, in depth, the sample requirements, experimental design, NGS platform specific challenges, and workflow for gene enrichment, library prep and sequencing. The applications of QIASeq RNA Panels in cancer research, stem cell differentiation and elucidating the effects small molecules on signaling pathways will be highlighted.
Molecular insight into Gene Expression Using Digital RNAseq: Digital RNAseq W...QIAGEN
Gene expression profiling is the key to understanding biological pathways and complex cellular systems. In this webinar we will discuss the challenges of targeted RNA-seq data analysis and present the solutions provided by the QIAGEN automated online data analysis tools. Using raw sequencing data from targeted sequencing, the output of the QIAseq primary data analysis tool and the options in QIAseq secondary analysis, such as normalization strategies, will be described. The use of Ingenuity Pathway Analysis (IPA) to unlock the molecular insights buried in experimental data by quickly identifying relationships, mechanisms, functions, and pathways of relevance will be shown with an example.
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...QIAGEN
Pancreatic cancer is a uniquely lethal malignancy characterized by frequent mutations in KRAS, CDKN2A, SMAD4, TP53 and many others. We have shown that KRAS mutation can be detected in cell-free, circulating tumor DNA (ctDNA) isolated from the plasma in a subset of patients and is associated with poor prognosis. The ability to simultaneously detect multiple pancreatic cancer-specific mutations in ctDNA would open a new avenue for detection of clinically-relevant mutations. In this study, we performed ultra-deep sequencing of ctDNA from advanced pancreatic cancer patients prior to treatment with Gemcitabine and Erlotinib following target enrichment. Somatic, non-synonymous variants were identified in 29 different genes at allele frequencies typically less than 0.5%. Updated results of ultra-deep NGS analysis will be presented.
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...QIAGEN
Targeted amplicon sequencing is a cost-effective, convenient and rapid method for variant detection. This application note outlines a straightforward workflow that uses the QIAseq 1-Step Amplicon Library kit to verify AmpliSeq targeted sequencing assays on the Illumina sequencing instruments. By combining end-repair and ligation, the QIAseq 1-Step Amplicon Library Kit offers a fast and efficient 30-minute procedure for the preparation of high-quality, artifact-free Illumina libraries from any PCR amplicons, including AmpliSeq Panels.
Digital DNA-seq Technology: Targeted Enrichment for Cancer ResearchQIAGEN
Targeted DNA sequencing has become a powerful approach by achieving high coverage of the region of interest while keeping the cost of sequencing and complexity of data interpretation manageable. However, existing PCR-based target enrichment approaches introduce errors due to PCR amplification bias and artifacts, which significantly affects quantification accuracy and limit the ability to confidently detect low-frequency DNA variants. This webinar introduces a new digital sequencing approach that is based on the use of unique molecular indices (UMIs) - QIAseq Targeted DNA Panels. With UMIs, each unique DNA molecule is barcoded before any amplification takes place to correct for PCR errors. Detailed workflow and applications in cancer research will be presented. Join us and learn about this exciting novel digital DNAseq technology
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...QIAGEN
Pyrosequencing is a highly flexible technology based on sequencing-by-synthesis for the rapid and quantitative analysis of any type of sequence variation. The real-time output delivers high-resolution sequence information, making pyrosequencing highly suitable for applications ranging from biallelic or multiallelic SNP analysis, DNA methylation quantification to complex mutation analysis of multiple sequence variations in a single run.
In this slideeck, we introduce the new PyroMark Q48 Autoprep system which enables fully automated template preparation integrated in the pyrosequencing workflow. In addition, a new Multiple Primer Dispensation (MPD) strategy is presented which allows fully automated dispensation of sequencing primer, offering a seamless workflow from samples to quantitative genotyping results.
This slidedeck focuses on the following topics
• Pyrosequencing technology and workflow in genotyping analysis
• Introduction into the new PyroMark Q48 Autoprep
• MPD strategy for a seamless automated pyrosequencing workflow
Join us and learn how you can apply the new pyrosequencing system and protocol to your variant analysis or genotyping research
Molecular QC: Using Reference Standards in NGS PipelinesCandy Smellie
Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run.
By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications.
Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.
Molecular QC: Interpreting your Bioinformatics PipelineCandy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all!
FFPE artifacts increase with storage time
Artifacts go against the statistical power of your variant calling analysis
Molecular reference standards help filter out bad mappings and spurious variants
Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline
Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis
NIST and its collaborators shared datasets created with most NGS technologies
Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio
~35K variants are predicted having high or moderate impact within the Trio
GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother
Routinely monitor the performance of your workflows and assays with independent external controls
This slidedeck details two comprehensive informatics solutions — the Biomedical Genomics Workbench and Ingenuity Knowledge Base Variant Analysis platforms. We show the intuitive user interface of CLC Cancer Research Workbench and demonstrate how the rich biological content from Ingenuity Knowledge Base helps you rapidly identify critical variants in your samples.
Digital RNAseq for Gene Expression Profiling: Digital RNAseq Webinar Part 2QIAGEN
Traditional RNA sequencing (RNA-Seq) is a powerful tool for expression profiling, but is hindered by PCR amplification bias and inaccuracy at low expressing genes. QIAseq RNA is a flexible and precise tool developed for mitigating these complications, allowing digital gene expression analysis. In this webinar we will cover, in depth, the sample requirements, experimental design, NGS platform specific challenges, and workflow for gene enrichment, library prep and sequencing. The applications of QIASeq RNA Panels in cancer research, stem cell differentiation and elucidating the effects small molecules on signaling pathways will be highlighted.
Molecular insight into Gene Expression Using Digital RNAseq: Digital RNAseq W...QIAGEN
Gene expression profiling is the key to understanding biological pathways and complex cellular systems. In this webinar we will discuss the challenges of targeted RNA-seq data analysis and present the solutions provided by the QIAGEN automated online data analysis tools. Using raw sequencing data from targeted sequencing, the output of the QIAseq primary data analysis tool and the options in QIAseq secondary analysis, such as normalization strategies, will be described. The use of Ingenuity Pathway Analysis (IPA) to unlock the molecular insights buried in experimental data by quickly identifying relationships, mechanisms, functions, and pathways of relevance will be shown with an example.
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...QIAGEN
Pancreatic cancer is a uniquely lethal malignancy characterized by frequent mutations in KRAS, CDKN2A, SMAD4, TP53 and many others. We have shown that KRAS mutation can be detected in cell-free, circulating tumor DNA (ctDNA) isolated from the plasma in a subset of patients and is associated with poor prognosis. The ability to simultaneously detect multiple pancreatic cancer-specific mutations in ctDNA would open a new avenue for detection of clinically-relevant mutations. In this study, we performed ultra-deep sequencing of ctDNA from advanced pancreatic cancer patients prior to treatment with Gemcitabine and Erlotinib following target enrichment. Somatic, non-synonymous variants were identified in 29 different genes at allele frequencies typically less than 0.5%. Updated results of ultra-deep NGS analysis will be presented.
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...QIAGEN
Targeted amplicon sequencing is a cost-effective, convenient and rapid method for variant detection. This application note outlines a straightforward workflow that uses the QIAseq 1-Step Amplicon Library kit to verify AmpliSeq targeted sequencing assays on the Illumina sequencing instruments. By combining end-repair and ligation, the QIAseq 1-Step Amplicon Library Kit offers a fast and efficient 30-minute procedure for the preparation of high-quality, artifact-free Illumina libraries from any PCR amplicons, including AmpliSeq Panels.
Digital DNA-seq Technology: Targeted Enrichment for Cancer ResearchQIAGEN
Targeted DNA sequencing has become a powerful approach by achieving high coverage of the region of interest while keeping the cost of sequencing and complexity of data interpretation manageable. However, existing PCR-based target enrichment approaches introduce errors due to PCR amplification bias and artifacts, which significantly affects quantification accuracy and limit the ability to confidently detect low-frequency DNA variants. This webinar introduces a new digital sequencing approach that is based on the use of unique molecular indices (UMIs) - QIAseq Targeted DNA Panels. With UMIs, each unique DNA molecule is barcoded before any amplification takes place to correct for PCR errors. Detailed workflow and applications in cancer research will be presented. Join us and learn about this exciting novel digital DNAseq technology
Presentation by Justin Zook at GRC/GIAB ASHG 2017 workshop "Getting the most from the reference assembly and reference materials" on benchmarks for indels and structural variants.
Course: Bioinformatics for Biomedical Research (2014).
Session: 4.1- Introduction to RNA-seq and RNA-seq Data Analysis.
Statistics and Bioinformatisc Unit (UEB) & High Technology Unit (UAT) from Vall d'Hebron Research Institute (www.vhir.org), Barcelona.
QIAseq Targeted DNA, RNA and Fusion Gene PanelsQIAGEN
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are some inherent challenges associated with it. These include false positives, gaps in the gene due to overrepresentation and incomplete representation of low-frequency transcripts – all contributing to an inaccurate picture. Conventional library prep strategies for NGS are based on PCR, which introduces sequence-based bias and amplification noise, leading to these inaccuracies. In this webinar, we will cover
1. Principles of UMI and the new QIAseq product porfolio
2. How UMI along with SPE (single primer extension) allows for increased uniformity across difficult-to-sequence regions, removal of library construction bias, improved data analysis and sequencing optimization
3. How data generated from using UMI and SPE is directly comparable to analysis derived from whole transcriptome and exome sequencing
4. Application of UMI and SPE in the discovery of novel gene fusions and in the analysis of gene expression and genetic variation
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Are There Any Natural Remedies To Treat Syphilis.pdf
Genome in a bottle for amp GeT-RM 181030
1. Genome in a Bottle: Benchmark for Structural
Variant Calls and New Data
Justin Zook, on behalf of the GIAB Consortium
NIST Human Genomics Team
October 30, 2018
2. Why Genome in a Bottle?
• A map of every individual’s genome
will soon be possible, but how will
we know if it is correct?
• Diagnostics and precision medicine
require high levels of confidence
• Well-characterized, broadly
disseminated genomes are needed
to benchmark performance of
sequencing
• Open, transparent data/analyses
• Enable technology development,
optimization, and demonstration
O’Rawe et al, Genome Medicine, 2013
https://doi.org/10.1186/gm432
3. GIAB is evolving with technologies
2012
• No human
benchmark
calls available
• GIAB
Consortium
formed
2014
• Small variant
genotypes
for ~77% of
pilot genome
NA12878
2015
• NIST releases
first human
genome
Reference
Material
2016
• 4 new
genomes
• Small
variants for
90% of 5
genomes for
GRCh37/38
2017+
• Characteriz-
ing difficult
variants
• Develop
tumor
samples
4. GIAB has characterized 7 human genomes
• Pilot genome
– NA12878
• PGP Human Genomes
– Ashkenazi Jewish son
– Ashkenazi Jewish trio
– Chinese son
• Parents also characterized
National I nstituteof S tandards & Technology
Report of I nvestigation
Reference Material 8391
Human DNA for Whole-Genome Variant Assessment
(Son of Eastern European Ashkenazim Jewish Ancestry)
This Reference Material (RM) is intended for validation, optimization, and process evaluation purposes. It consists
of a male whole human genome sample of Eastern European Ashkenazim Jewish ancestry, and it can be used to assess
performance of variant calling from genome sequencing. A unit of RM 8391 consists of a vial containing human
genomic DNA extracted from a single large growth of human lymphoblastoid cell line GM24385 from the Coriell
Institute for Medical Research (Camden, NJ). The vial contains approximately 10 µg of genomic DNA, with the peak
of the nominal length distribution longer than 48.5 kb, as referenced by Lambda DNA, and the DNA is in TE buffer
(10 mM TRIS, 1 mM EDTA, pH 8.0).
This material is intended for assessing performance of human genome sequencing variant calling by obtaining
estimates of true positives, false positives, true negatives, and false negatives. Sequencing applications could include
whole genome sequencing, whole exome sequencing, and more targeted sequencing such as gene panels. This
genomic DNA is intended to be analyzed in the same way as any other sample a lab would process and analyze
extracted DNA. Because the RM is extracted DNA, it is not useful for assessing pre-analytical steps such as DNA
extraction, but it does challenge sequencing library preparation, sequencing machines, and the bioinformatics steps of
mapping, alignment, and variant calling. This RM is not intended to assess subsequent bioinformatics steps such as
functional or clinical interpretation.
Information Values: Information values are provided for single nucleotide polymorphisms (SNPs), small insertions
and deletions (indels), and homozygous reference genotypes for approximately 88 % of the genome, using methods
similar to described in reference 1. An information value is considered to be a value that will be of interest and use to
the RM user, but insufficient information is available to assess the uncertainty associated with the value. We describe
and disseminate our best, most confident, estimate of the genotypes using the data and methods currently available.
These data and genomic characterizations will be maintained over time as new data accrue and measurement and
informatics methods become available. The information values are given as a variant call file (vcf) that contains the
high-confidence SNPs and small indels, as well as a tab-delimited “bed” file that describes the regions that are called
high-confidence. Information values cannot be used to establish metrological traceability. The files referenced in this
report are available at the Genome in a Bottle ftp site hosted by the National Center for Biotechnology Information
(NCBI). The Genome in a Bottle ftp site for the high-confidence vcf and high confidence regions is:
https://doi.org/10.1101/281006
Latest small variant characterization:
New!
5. Open consent enables secondary reference samples
• >30 products now available
based on broadly-consented,
well-characterized GIAB PGP cell
lines
• Genomic DNA + DNA spike-ins
– Clinical variants
– Somatic variants
– Difficult variants
• Clinical matrix (FFPE)
• Circulating tumor DNA
• Stem cells (iPSCs)
• Genome editing
• …
6. All data and analyses are open and public
51 authors
14 institutions
12 datasets
7 genomes
Data described in ISA-tab
New data on GIAB NCBI FTP
8. GIAB “Open Science” Virtuous Cycle
Users
analyze
GIAB
Samples
Benchmark
vs. GIAB
data
Critical
feedback
to GIAB
Integrate
new
methods
New
benchmark
data
Method
development,
optimization, and
demonstration
Part of assay
validation
GIAB/NIST
expands to more
difficult variants
9. Best Practices for Benchmarking Small Variants
https://github.com/ga4gh/benchmarking-tools
https://doi.org/10.1101/270157 https://precision.fda.gov/
Describe public
“Truth” VCFs
with confident
regions
Enable
stratification of
performance in
difficult regions
Tools to compare
different
representations of
complex variants Standardized
VCF-I output of
comparison
tools
Standardized
output formats for
performance
metrics
Web-based interface for
performance metrics
Standardized
definitions of
performance metrics
based on matching
stringency
10. What are we accessing and what is still
challenging?
Type of variant Genome
context
Fraction
of variants
called*
Number of
variants
missing*
How to improve?
Simple SNPs Not repetitive ~97% >100k Machine learning
Simple indels Not repetitive ~93% >10k Machine learning
All variants Low
mappability
<30% >170k Use linked reads and long
reads
All variants Regions not in
GRCh37/38
0 >>100k??? De novo assembly; long reads
Small indels Tandem repeats
and
homopolymers
<50% >200k STR/homopolymer callers; long
reads; better handle complex
and compound variants
Indels 15-50bp All <25% >30k Assembly-based callers;
integrate larger variants
differently; long reads
Indels >50bp All <1% >20k
* Approximate values based on fraction of variants in GATKHC or FermiKit that are
inside v3.3.2 High-confidence regions
11. How can we extend our approach to structural
variants?
Similarities to small variants
• Collect callsets from multiple
technologies
• Compare callsets to find calls
supported by multiple technologies
Differences from small variants
• Callsets have limited sensitivity
• Variants are often imprecisely
characterized
– breakpoints, size, type, etc.
• Representation of variants is poorly
standardized, especially when complex
• Comparison tools in infancy
12. Integration of diverse data types and analyses
• Data publicly available
– Deep short reads
– Linked reads
– Long reads
– Optical/nanopore mapping
• Analyses
– Small variant calling
– SV calling
– Local and global assembly
Discover &
Refine
sequence-
resolved calls
from multiple
datasets &
analyses Compare
variant and
genotype calls
from different
methods
Evaluate/
genotype calls
with other
data
Identify
features
associated
with reliability
of calls from
each method
Form
benchmark
calls using
heuristics &
machine
learning
Compare
benchmarks
to high-
quality
callsets and
examine
differences
13. V0.6 SV Benchmark Set
• Tier 1 regions contain 2.68 Gbp
with 11,869 isolated SVs >49bp
• Tier 1 calls meet the criteria:
• Discovered by 2+ techs or 5+
callers
• Confirmed and genotyped by
long reads
• Not disproven by any
technology
• Clusters of calls within 1000bp are
excluded
• Regions around calls 20-49bp are
excluded
Benchmark set and README at tinyurl.com/GIABSV06
Blue - clustered calls
Red - isolated calls
50 to 1000 bp
Alu Alu
1kbp to 10kbp
LINE LINE
14. Can you trust the SV benchmark results?
• Important to use sophisticated
benchmarking tools
• github.com/spiralgenetics/truvari
• github.com/nhansen/SVanalyzer
• Volunteers compared to v0.6 Tier 1
• Stratified by variant type and
overlap with tandem repeat
• Manually curated 10 random
putative FPs and FNs from each
category
• Short reads vs v0.6
• >90% of putative FPs and FNs
are errors from short reads
• Long reads vs. v0.6
• >90% of putative FNs are
errors from long read methods
• ~50% of putative FP insertions
appear to be real missed
variants in v0.6
Draft SV calls: tinyurl.com/GIABSV06
17. SV Example: Homozygous 1300bp Insertion in Tandem Repeat
PacBio
CCS
Oxford
Nanopore
Illumina
18. SV Example: Complex and Compound SV Region
PacBio
CCS
Oxford
Nanopore
Illumina
19. SV Example: Complex and Compound SV Region
Credit: Joyce Lee, BioNano Genomics
20. Crowd-sourced manual curation agrees with SV benchmark
www.svcurator.com
● Candidates examined by
11 curators on average
● 627/635 consensus manual
curations agreed with v0.6
genotype in benchmark
regions
○ Most “discordant” sites
related to inclusion of 20-
49bp indels in curation
Credit: Lesley Chapman
21. Oxford Nanopore “Ultralong reads”
Noah Spies
David Catoe
Marc Salit
Matt Loose
Nick Loman
Josh Quick
Nate Olson
Miten Jain
Karen Miga
Hugh Olson
Benedict Paten
• Second release:
• 16x total mapped
• 8x reads > 50kb
• 4x reads > 100kb
• Estimated 30x total in
2018
• Starting work with UCSC
on Promethion
sequencing of all GIAB
genomes
• See Miten Jain talk
from GRC/GIAB
22. Improving small variants with long reads
Raw ONT/PacBio long reads
• New methods use phasing to call
accurate SNVs despite high error
rate
• SNV precision and recall can be
>99% vs. current benchmark
• Indels are still challenging
PacBio Long CCS
• New 10kb and 15kb reads with
low error rate
• Enables SNV and indel calling with
methods developed for short
reads
• SNV precision & recall >99.9%
– Most errors in homopolymers
– Fixes some short read errors in
LINEs
• Indel precision & recall >97%
– Most errors in homopolymers
Jana Ebler/Tobias Marschall
Trevor Pesout/Benedict Paten
Vikas Bansal
Ruibang Luo/Fritz Sedlazeck/Mike Schatz
Aaron Wenger/Billy Rowell/Luke Hickey
Jason Chin
Andrew Carroll, Pi-Chuan Chang, Mark DePristo, Alexey Kolesnikov
Data public without embargo: ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/
23. Challenges in Benchmarking Variant Calling
• It is difficult to do robust benchmarking of tests designed to
detect many analytes (e.g., many variants)
• Best to benchmark only within high-confidence bed file, but…
• Benchmark calls/regions tend to be biased towards easier
variants and regions
– Some clinical tests are enriched for difficult sites
• Always manually inspect a subset of FPs/FNs
• Stratification by variant type and region is important
• Always calculate confidence intervals on performance metrics
24. The road ahead...
2018
• Further
automate
integration
• Large
variants
• Difficult
small
variants
• Phasing
2019
• Difficult
small & large
variants
• Somatic
sample
development
• Germline
samples from
new
ancestries
2020+
• Diploid
assembly
• Somatic
structural
variation
• Segmental
duplications
• Centromere/
telomere
• ...
25. Take-home Messages
• Genome in a Bottle is:
– “Open science”
– Authoritative characterization of human genomes
• Currently enable benchmarking of “easier” variants
– Clinical validation
– Technology development, optimization, and demonstration
• Now working on difficult variants and regions
– Draft benchmark set >=50bp + confident regions
– Many challenges remain and collaborations welcome!
Draft SV calls: ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/analysis/NIST_SVs_Integration_v0.6/
26. Acknowledgements
• NIST
– Lesley Chapman
– Nate Olson
– Justin Wagner
– Jenny McDaniel
– Lindsay Harris
• JIMB
– Marc Salit
– Noah Spies
– David Catoe
• FDA
• GA4GH Benchmarking Team
• Genome in a Bottle Consortium
28. For More Information
www.genomeinabottle.org - sign up for general GIAB and Analysis Team google group
github.com/genome-in-a-bottle – Guide to GIAB data & ftp
www.slideshare.net/genomeinabottle
Latest small variant benchmark: https://doi.org/10.1101/281006
Data:
– http://www.nature.com/articles/sdata201625
– ftp://ftp-trace.ncbi.nlm.nih.gov/giab/
Global Alliance Benchmarking Team
– https://github.com/ga4gh/benchmarking-tools
– Web-based implementation at precision.fda.gov
– Best Practices at https://doi.org/10.1101/270157
Public workshops
– Next workshop planned for Spring 2019 at Stanford University, CA, USA
Justin Zook: jzook@nist.gov
NIST postdoc
opportunities
available!